Compare BIVI & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIVI | PRSO |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 13.4M |
| IPO Year | 2013 | 2000 |
| Metric | BIVI | PRSO |
|---|---|---|
| Price | $1.22 | $0.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.26 | N/A |
| AVG Volume (30 Days) | ★ 254.9K | 162.8K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.83 | ★ 81.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,573,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $191.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.99 |
| 52 Week Low | $0.82 | $0.38 |
| 52 Week High | $3.79 | $2.37 |
| Indicator | BIVI | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 23.51 |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.32 | $0.52 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 2.73 | 9.47 |
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.